Eli Lilly and Company (LLY)
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly Is Putting On Some Weight As Earnings Near
Eli Lilly and Company has shown rapid growth, driven by its weight loss drugs Mounjaro and Zepbound, with significant revenue increases. Despite impressive growth, I maintain a 'hold' rating due to the stock's high valuation, which I find prohibitive. Analysts expect strong Q3 2024 results, with projected revenue of $12.11 billion and adjusted net income of $1.31 billion.
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lilly's Alzheimer's drug approved in the UK
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Fewer contenders means fewer constraints on expanding market share.
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Eli Lilly Buy On Weakness Signal (Technical Analysis)
Eli Lilly has triggered multiple Buy signals, including Timing, SAR, and Fundamental, with a 12-month target of ~$1,150. Technical indicators like Full Stochastic, Chaikin money flow, and ADX Demand signal show bullish trends and outperformance versus the Index. Despite strong Growth, Momentum, and Profitability scores, poor Valuation and Revision scores make LLY risky, leading to potential selling on good news.
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Eli Lilly just secured a huge win, and it's not related to the weight loss industry.
Lilly Loses Around $14B This Week: How to Play LLY Stock
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
2 High-Flying Growth Stocks With Massive Upside Potential
These innovative drugmakers have potential catalysts ahead.
